Home Cart Sign in  
Chemical Structure| 2225819-06-5 Chemical Structure| 2225819-06-5

Structure of BAY-2402234
CAS No.: 2225819-06-5

Chemical Structure| 2225819-06-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BAY 2402234 is a novel and selective dihydroorotate dehydrogenase (DHODH) inhibitor. It potently inhibited proliferation of AML cell lines in the sub-nanomolar to low-nanomolar range in vitro and exhibited strong in vivo anti-tumor efficacy in monotherapy in several subcutaneous and disseminated AML xenografts as well as AML patient-derived xenograft (PDX) models.

Synonyms: Orludodstat

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BAY-2402234

CAS No. :2225819-06-5
Formula : C21H18ClF5N4O4
M.W : 520.84
SMILES Code : O=C(NC1=C(F)C=CC=C1Cl)C2=CC(F)=C(N3N=C(CO)N(CC)C3=O)C=C2O[C@@H](C)C(F)(F)F
Synonyms :
Orludodstat
MDL No. :MFCD31692414
InChI Key :KNVJMHHAXCPZHF-JTQLQIEISA-N
Pubchem ID :134470179

Safety of BAY-2402234

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
ST cells 10 nM 24 hours Inhibited CSFV replication J Virol. 2024 Jun 13;98(6):e0049424.
Calu-3 cells 1 μM 48 hours Evaluate the inhibitory effect of NHC and DHODH inhibitors on SARS-CoV-2 replication, results showed combination treatment significantly reduced viral RNA yield iScience. 2022 May 20;25(5):104293.
Vero E6 cells 1 μM 48 hours Evaluate the inhibitory effect of NHC and DHODH inhibitors on SARS-CoV-2 replication, results showed combination treatment significantly reduced viral RNA yield iScience. 2022 May 20;25(5):104293.
PK-15 cells 10 nM 24 hours Inhibited CSFV replication with EC50 of 0.975 nM J Virol. 2024 Jun 13;98(6):e0049424.
Malignant rhabdoid tumor (MRT) tumoroids 50 nM 120 hours Inhibition of nucleotide synthesis, reducing nucleotide levels and inducing apoptosis Cell Rep Med. 2025;6(1):101878.
IPEC-J2 cells 10 nM 24 hours Inhibited CSFV replication with higher sensitivity compared to PK-15 and BHK cells J Virol. 2024 Jun 13;98(6):e0049424.
Atypical teratoid/rhabdoid tumor (AT/RT) tumoroids 50 nM 120 hours Inhibition of nucleotide synthesis, reducing nucleotide levels and inducing apoptosis Cell Rep Med. 2025;6(1):101878.
GSC lines (MGG152, BT054, BT260, HK157) 3 nM or 10 nM 4-5 days To evaluate the cytotoxic effect of BAY-2402234 on IDH1-mutant GSC lines, results showed that IDH1-mutant cells were more sensitive to BAY-2402234. Cancer Cell. 2022 Sep 12;40(9):939-956.e16.
HOG-R132H cells 10 nM 72 hours To evaluate the cytotoxic effect of BAY-2402234 on IDH1-mutant cells, results showed that IDH1-mutant cells were more sensitive to BAY-2402234. Cancer Cell. 2022 Sep 12;40(9):939-956.e16.
HuH7 cells 5 nM 48 hours Inhibits DHODH enzyme activity, synergistically inhibits HCC cell proliferation and survival when combined with Palbociclib. J Biol Chem. 2023 Dec;299(12):105407.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MGG152 orthotopic xenograft model Oral 4 mg/kg Once daily for 3 days To evaluate the antitumor activity of BAY-2402234 in vivo, results showed that BAY-2402234 significantly prolonged the survival of mice bearing IDH1-mutant tumors. Cancer Cell. 2022 Sep 12;40(9):939-956.e16.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.92mL

0.38mL

0.19mL

9.60mL

1.92mL

0.96mL

19.20mL

3.84mL

1.92mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories